{"filing":{"accession_number":"0001193125-26-406063","cik":"0001936258","ticker":"NAMSW","company_name":"NewAmsterdam Pharma Co N.V.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"nams-20260929.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526406063/nams-20260929.htm"},"events":[{"id":35623,"run_id":32820,"accession_number":"0001193125-26-406063","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"NewAmsterdam announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in preclinical Alzheimer's disease. This represents a material clinical development milestone—expansion of the company's pipeline into a new indication (neurodegenerative disease) and advancement of a key product candidate. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's development progress and market opportunity.","company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMSW","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39746,"accession_number":"0001193125-26-406063","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NewAmsterdam announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in preclinical Alzheimer's disease. This represents a material clinical development milestone—expansion of the company's pipeline into a new indication (neurodegenerative disease) and advancement of a key product candidate. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's development progress and market opportunity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T12:23:49.151156+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39746,"accession_number":"0001193125-26-406063","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NewAmsterdam announced the dosing of the first patient in SPINOZA, a Phase 2b clinical trial evaluating obicetrapib in preclinical Alzheimer's disease. This represents a material clinical development milestone—expansion of the company's pipeline into a new indication (neurodegenerative disease) and advancement of a key product candidate. While not a specific named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's development progress and market opportunity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T12:23:49.151156+00:00","company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMSW","filing_date":"2026-09-29"}]}